[Efficacy of cytoprotective agent Mexicor in urgent cardiology]

Insights

Mexicor improves outcomes for patients with unstable angina, myocardial infarction, and hypertensive crises. This cytoprotector reduces oxidant stress and enhances cardiac recovery when added to conventional treatments.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ischemic heart disease (IHD) and arterial hypertension (AH) are significant cardiovascular conditions.
  • Acute forms of IHD and AH crises require effective therapeutic interventions.

Purpose of the Study:

  • To evaluate the efficacy of the cytoprotector mexicor as an adjunct therapy.
  • To assess mexicor's impact on unstable angina (UA), acute myocardial infarction (MI), and hypertensive crises (HC).

Main Methods:

  • An open randomized study involving 338 patients with acute IHD and AH.
  • Patients received conventional therapy with or without mexicor (6-9 mg/kg/day).
  • Evaluations included echocardiography, ECG, 24-h blood pressure monitoring, and lipid peroxidation (LPO) assessment.

Main Results:

  • Mexicor diminished oxidant stress and improved left ventricular dysfunction.
  • In MI patients, mexicor reduced akinetic zones and improved contractility.
  • Mexicor enhanced angina stabilization in UA patients and normalized AP profiles in HC patients, halving HC recurrence.

Conclusions:

  • Adjunctive mexicor therapy improves the clinical course of UA, MI, and HC.
  • Mexicor reduces oxidant stress and accelerates cardiac recovery.
  • The addition of mexicor aids in the normalization of central hemodynamics and cardiac rhythm variability.
Abstract

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...